Call: +7 771 977 66 65, +7 705 421 2277
Sign in or Register
My basket

Astana Biomed Group, an authorized Abcam distributor in Central Asia

Abiomed homepage

  • Categories
    Signal Transduction
    Cancer
    Epigenetics and Nuclear Signaling
    Immunology
    Cell Biology
    Cardiovascular
    Neuroscience
    Tags & Cell Markers
    Kits/ Lysates/ Other
    Developmental Biology
    Microbiology
    Biochemicals
    Secondary antibodies
    Isotype/Loading Controls
    Antibody Arrays
  • About us
  • Partners
  • Contact
    Address

    Saryarka 32, 18, 010000, Astana city, Kazakhstan

    Telephone +7 771 977 66 65, +7 705 421 2277

    Email

    laboratory@ctlab.kz, orders@abiomed.kz

Back to category
Epigenetics and Nuclear Signaling Transcription Other factors

Human SMURF2 knockout HeLa cell pellet (ab279247)

Price and availability

670 ₸

Availability

Order now and get it on Tuesday March 09, 2021

Human SMURF2 knockout HeLa cell pellet (ab279247)
  • ChIP - Anti-Histone H3 antibody - Nuclear Loading Control and ChIP Grade (ab1791)
  • ChIP - Anti-Histone H3 antibody - Nuclear Loading Control and ChIP Grade (ab1791)
  • ChIP - Anti-Histone H3 antibody - Nuclear Loading Control and ChIP Grade (ab1791)

You may also be interested in

Product image
Anti-NFIC/CTF antibody (ab245597)
Product image
Alexa Fluor® 647 Anti-TLE 1 antibody [EPR9386(2)] (ab198525)
Product image
Anti-TZFP/ZBTB32 antibody (ab235306)
Product image
Anti-HNF1 alpha + HNF-1B antibody [EPR18644] (ab209666)

Overview

  • Product name

    Human SMURF2 knockout HeLa cell pellet
    See all SMURF 2 kits
  • Product overview

    Abcam’s knockout cell pellets give you access to native proteins, without the need to culture cells. Our knockout cell pellets are prepared from our single-gene knockout cell lines and provide an additional offering to our cell lysates.

    Cells are snap-frozen to provide high quality pellets that are suitable for extraction with alternative lysis buffers or for preparation of lysates from subcellular fractions. Our knockout cell pellets are suitable for a variety of applications, including PCR, gene expression profiling and DNA library preparation.

  • Parental Cell Line

    HeLa
  • Organism

    Human
  • Mutation description

    Knockout achieved by using CRISPR/Cas9, 1 bp insertion in exon 5 and 5 bp deletion in exon 5.
  • Passage number

  • Knockout validation

    Sanger Sequencing, Western Blot (WB)
  • Notes

    Pellet size: 5 million cells/vial.

    This product is subject to limited use licenses from The Broad Institute, ERS Genomics Limited and Sigma-Aldrich Co. LLC, and is developed with patented technology. For full details of the licenses and patents please refer to our limited use license and patent pages.

  • Tested applications

    Suitable for: WBmore details

Properties

  • Storage instructions

    Store at -80°C. Please refer to protocols.
  • Components 1 kit
    Human SMURF2 knockout HeLa cell pellet 1 vial
    Human wild-type HeLa cell pellet 1 vial
  • Research areas

    • Epigenetics and Nuclear Signaling
    • Transcription
    • Other factors
    • Stem Cells
    • Signaling Pathways
    • TGF beta
    • Cytoplasmic
  • Cell type

    epithelial
  • Disease

    Adenocarcinoma
  • Gender

    Female
  • STR Analysis

    Amelogenin X D5S818: 11, 12 D13S317: 12, 13.3 D7S820: 8, 12 D16S539: 9, 10 vWA: 16, 18 TH01: 7 TPOX: 8, 12 CSF1PO: 9, 10

Target

  • Function

    E3 ubiquitin-protein ligase which accepts ubiquitin from an E2 ubiquitin-conjugating enzyme in the form of a thioester and then directly transfers the ubiquitin to targeted substrates. Interacts with SMAD1 and SMAD7 in order to trigger their ubiquitination and proteasome-dependent degradation. In addition, interaction with SMAD7 activates autocatalytic degradation, which is prevented by interaction with SCYE1. Forms a stable complex with the TGF-beta receptor-mediated phosphorylated SMAD2 and SMAD3. In this way, SMAD2 may recruit substrates, such as SNON, for ubiquitin-mediated degradation. Enhances the inhibitory activity of SMAD7 and reduces the transcriptional activity of SMAD2. Coexpression of SMURF2 with SMAD1 results in considerable decrease in steady-state level of SMAD1 protein and a smaller decrease of SMAD2 level.
  • Tissue specificity

    Widely expressed.
  • Pathway

    Protein modification; protein ubiquitination.
  • Sequence similarities

    Contains 1 C2 domain.
    Contains 1 HECT (E6AP-type E3 ubiquitin-protein ligase) domain.
    Contains 3 WW domains.
  • Domain

    The second and third WW domains are responsible for interaction with the PY-motif of R-SMAD (SMAD1, SMAD2 and SMAD3).
    The C2 domain is involved in autoinhibition of the catalytic activity by interacting with the HECT domain.
  • Post-translational
    modifications

    Auto-ubiquitinated and ubiquitinated in the presence of RNF11 and UBE2D1.
  • Cellular localization

    Nucleus. Cytoplasm. Cell membrane. Membrane raft. Cytoplasmic in the presence of SMAD7. Co-localizes with CAV1, SMAD7 and TGF-beta receptor in membrane rafts.
  • Target information above from: UniProt accession Q9HAU4 The UniProt Consortium
    The Universal Protein Resource (UniProt) in 2010
    Nucleic Acids Res. 38:D142-D148 (2010) .

    Information by UniProt
  • Alternative names

    • E3 ubiquitin-protein ligase SMURF2
    • EC 6.3.2.
    • hSMURF2
    • MGC138150
    • Smad specific E3 ubiquitin ligase 2
    • SMAD specific E3 ubiquitin protein ligase 2
    • SMAD ubiquitination regulatory factor 2
    • SMAD-specific E3 ubiquitin-protein ligase 2
    • SMUF2_HUMAN
    • Smurf2
    • Ubiquitin protein ligase SMURF2
    see all

Properties

  • Storage instructions

    Store at -80°C. Please refer to protocols.
  • Components 1 kit
    Human SMURF2 knockout HeLa cell pellet 1 vial
    Human wild-type HeLa cell pellet 1 vial
  • Research areas

    • Epigenetics and Nuclear Signaling
    • Transcription
    • Other factors
    • Stem Cells
    • Signaling Pathways
    • TGF beta
    • Cytoplasmic
  • Cell type

    epithelial
  • Disease

    Adenocarcinoma
  • Gender

    Female
  • STR Analysis

    Amelogenin X D5S818: 11, 12 D13S317: 12, 13.3 D7S820: 8, 12 D16S539: 9, 10 vWA: 16, 18 TH01: 7 TPOX: 8, 12 CSF1PO: 9, 10

Images

  • Western blot - Human SMURF2 knockout HeLa cell pellet (ab279247)
    Western blot - Human SMURF2 knockout HeLa cell pellet (ab279247)

    Lane 1:Wild-type HeLa cell lysate (20 ug)
    Lane 2:SMURF2 knockout HeLa cell lysate (20 ug)
    Lane 3:U-2 OS cell lysate (20 ug)

    ab53316 was shown to specifically react with SMURF 2 in wild-type HeLa cells. Loss of signal was observed when knockout cell line ab264806 (knockout cell lysate ab257690) was used. Wild-type and SMURF 2 knockout samples were subjected to SDS-PAGE. ab53316 and Anti-GAPDH antibody [6C5] - Loading Control (ab8245) were incubated at room temperature for 2.5 hours at 1 in 1000 dilution and 1 in 20000 dilution respectively. Blots were developed with Goat anti-Rabbit IgG H&L (IRDye® 800CW) preadsorbed (ab216773) and Goat anti-Mouse IgG H&L (IRDye® 680RD) preadsorbed (ab216776) secondary antibodies at 1 in 20000 dilution for 1 hour at room temperature before imaging.

  • Sanger Sequencing - Human SMURF2 knockout HeLa cell pellet (ab279247)
    Sanger Sequencing - Human SMURF2 knockout HeLa cell pellet (ab279247)

    Allele-1: 5 bp deletion in exon 5

     

  • Sanger Sequencing - Human SMURF2 knockout HeLa cell pellet (ab279247)
    Sanger Sequencing - Human SMURF2 knockout HeLa cell pellet (ab279247)

    Allele-2: 1 bp insertion in exon 5

     

Please note: All products are "FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES"
For licensing inquiries, please contact partnerships@abcam.com

Clear all

Recently viewed products

  •  
  • Product image

    Recombinant Human VMAT2 protein (ab112353)

  •  
  • Product image

    Anti-Acetylcholinesterase antibody - BSA and Azide free (Capture) (ab281269)

Get resources and offers direct to your inbox Sign up
© 2021 Astana Biomed Group LLP. All rights reserved.